A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2022-08-10
Target enrollment:
Participant gender:
Summary
Pazopanib is an angiogenesis inhibitor targeting VEGFR-1, -2, and -3; PDGFR-α and -β; and the
receptor c-Kit, and is indicated for the treatment of subjects with advanced renal cell
carcinoma (RCC) and advanced STS. For this orphan tumor, STS, PD-L1 targeting may be a
promising strategy and favorable toxicity may warrant further combination.